SEC Form 4 · accession 0001209191-18-038593

Verrica Pharmaceuticals Inc. · VRCA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Jun 19, 2018

Accepted (ET)

Jun 19, 2018 · 4:46 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001660334

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jun 19, 2018	C	7,754,783	—	A	7,754,783	D
Common Stock^F1,F2	Jun 19, 2018	C	1,132,900	—	A	1,160,244	I	See Footnote
Common Stock^F1,F3	Jun 19, 2018	C	256,634	—	A	256,634	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Convertible Preferred Stock^F1	—	Jun 19, 2018	C	7,754,783	D	—	—	Common Stock	7,754,783	D
Series A Convertible Preferred Stock^F2,F1	—	Jun 19, 2018	C	1,132,900	D	—	—	Common Stock	1,132,900	I
Series A Convertible Preferred Stock^F3,F1	—	Jun 19, 2018	C	256,634	D	—	—	Common Stock	256,634	I

F1Each share of Series A Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering.
F2The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB.
F3The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is President and CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.